An updated patent review of p38 MAP kinase inhibitors (2014-2019)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An updated patent review of p38 MAP kinase inhibitors (2014-2019)

Published:2020-04-20 Issue:6 Volume:30 Page:453-466
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Haller Vanessa¹,Nahidino Philipp¹,Forster Michael¹,Laufer Stefan A.¹²³

Affiliation:

1. Department of Pharmaceutical and Medicinal Chemistry, Eberhard Karls University Tübingen, Tübingen, Germany

2. Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Germany

3. Tübingen Center for Academic Drug Discovery & Development (TüCAD2)

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2020.1749263

Reference32 articles.

1. Activation and signaling of the p38 MAP kinase pathway

2. Mechanisms and functions of p38 MAPK signalling

3. The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells

4. TGF-β1 Induces Endothelial Cell Apoptosis by Shifting VEGF Activation of p38MAPKfrom the Prosurvival p38β to Proapoptotic p38α

5. MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. p38α Mitogen-Activated Protein Kinase—An Emerging Drug Target for the Treatment of Alzheimer’s Disease;Molecules;2024-09-13

2. Kinases Inhibitors as New Therapeutic Opportunities in Cutaneous T-Cell Lymphoma;Kinases and Phosphatases;2024-08-28

3. A first-in-kind MAPK13 inhibitor that can correct stem cell reprogramming and post-injury disease;2024-08-22

4. Molecular Determinants for Photodynamic Therapy Resistance and Improved Photosensitizer Delivery in Glioma;International Journal of Molecular Sciences;2024-08-09

5. MAPK13 controls structural remodeling and disease after epithelial injury;2024-06-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3